Cite
HARVARD Citation
Smith, S. et al. (n.d.). RAPID AND DURABLE RESPONSES WITH THE SYK/JAK INHIBITOR CERDULATINIB IN A PHASE 2 STUDY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA—ALONE OR IN COMBINATION WITH RITUXIMAB. Hematological oncology. pp. 61-62. [Online].